Dare Bioscience Files 8-K on Financials
Ticker: DARE · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1401914
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Dare Bioscience dropped an 8-K on Nov 13th covering financials - check it for the latest.
AI Summary
On November 13, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This 8-K filing provides an update on Dare Bioscience's financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high or medium risk.
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- November 13, 2025 (date) — Date of earliest event reported
- Cerulean Pharma Inc. (company) — Former company name
- Tempo Pharmaceuticals Inc (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Dare Bioscience, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K filing reported as of?
The filing was reported as of November 13, 2025.
What is Dare Bioscience, Inc.'s state of incorporation?
Dare Bioscience, Inc. is incorporated in Delaware.
What were Dare Bioscience's previous company names?
Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
What is the principal executive office address for Dare Bioscience, Inc.?
The principal executive office is located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-13 16:01:57
Filing Documents
- form8-k.htm (8-K) — 34KB
- ex99-1.htm (EX-99.1) — 71KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-25-022277.txt ( ) — 288KB
- dare-20251113.xsd (EX-101.SCH) — 3KB
- dare-20251113_lab.xml (EX-101.LAB) — 33KB
- dare-20251113_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: November 13, 2025 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer